This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A synthetically cyclised conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C-termini.

2. (Previously presented) A cyclised conotoxin peptide according to claim 1 having an activity associated with the therapeutic treatment of mammals.

3. (Currently amended) A cyclic conotoxin peptide according to claim 1 which contains or consists of the sequence of amino acids present in a naturally occurring conotoxin peptide ~~or derivative thereof~~.

4. (Original) A cyclic conotoxin peptide according to claim 3 wherein the naturally occurring conotoxin peptide is selected from MVIA, GVIA, SVIB, SVIA, TVIA, MVIIC, GVIIA, GVIIB, PVIIA, GS, GI, IMI, PNIA, PNIB, SII, MII, GIIIA, GIIIB, GIIIC and PIIIA.

5. (Previously presented) A cyclic conotoxin peptide according to claim 1 having three disulphide bonds in the form of a cysteine knot.

6. (Previously presented) A cyclic conotoxin peptide according to claim 1 comprising a linear conotoxin peptide and a peptide linker, wherein the N- and C- termini of the linear peptide are linked via the peptide linker to form an amide cyclised peptide backbone.

7. (Currently amended) A cyclic conotoxin peptide according to claim 6 wherein the linear conotoxin peptide moiety is ~~derived~~ obtained from a naturally occurring conotoxin peptide and retains the disulphide bond connectivity of the naturally occurring conotoxin peptide.

8. (Original) A cyclic conotoxin peptide according to claim 6 wherein the peptide linker is from 2 to 15 amino acids in length.

9. (Original) A cyclic conotoxin peptide according to claim 6 wherein the peptide linker is selected from the group consisting of:

TRNGLPG	SEQ ID NO. 1
TRNG	SEQ ID NO. 2
TRGGLPV	SEQ ID NO. 3
TNG	SEQ ID NO. 4

10. (Previously presented) A cyclic conotoxin peptide according to claim 1 selected from the group consisting of:

CKGKGAKCSRLMYDCCTGSCRSGKCTRNGLPG	SEQ. ID NO. 5
CKGKGAKCSRLMYDCCTGSCRSGKCTRNG	SEQ. ID NO. 6
GLPV**CKGKGAKCSRLMYDCCTGSCRSGKC**TRG	SEQ ID NO. 7
GCCSNPVCHLEHSNLCTNG	SEQ ID NO. 8
CCSNPVCHLEHSNLCTNG**G**	SEQ ID NO. 9

11. (Previously presented) A process for preparing a cyclic conotoxin according to claim 1 comprising:

(i) synthesizing an extended linear conotoxin peptide on a solid phase support, said extended linear conotoxin peptide comprising a linear conotoxin peptide having a linker moiety attached to at least one end thereof,

(ii) cleaving said extended linear peptide from the support

(iii) cyclising said extended linear conotoxin peptide, and

(iv) oxidizing said cyclised peptide to form disulphide bonds.

12. (Previously presented) A process for preparing a cyclic conotoxin according to claim 1 comprising:

(i) synthesizing an extended linear conotoxin peptide on a solid phase support, said extended linear conotoxin peptide comprising a linear conotoxin peptide having a linker moiety attached to at least one end thereof,

(ii) cleaving said linear peptide from the solid support,

(iii) subjecting said extended peptide to conditions such that the peptide folds and forms the required disulphide bonds, and

(iv) cyclising the folded peptide.

13. (Currently amended) A process for preparing a cyclic conotoxin according to claim 1 comprising:

(i) reacting a conotoxin peptide with a linker moiety to form an extended linear conotoxin peptide having said linker moiety attached to one end thereof, and

(ii) cyclising said extended peptide ~~and oxidizing to form disulphide bonds, if required~~.

14. (Currently amended) ~~Use of a cyclic conotoxin peptide according to claim 1 having activity at ion channel receptors as a neuropharmacological probe~~. A method for detecting a neurological disorder in a mammal including the step of administering an effective amount of a cyclic conotoxin peptide according to claim 1 to the mammal.

15. (Currently amended) A method ~~for the treatment or prophylaxis of conditions or diseases in mammals including~~ comprising the step of administering a pharmaceutically effective amount of a cyclic conotoxin peptide according to claim 1 to a mammal.

16. Canceled.

17. (Currently amended) A composition comprising a pharmaceutically effective amount of a cyclic conotoxin peptide according to claim 1 and a pharmaceutically acceptable carrier or diluent.

18. (Original) A composition according to claim 17 which is pharmaceutical composition.

19. (New) The process of claim 13, the process further comprising the step of oxidizing said extended peptide to form disulphide bonds.